Compounded GLP-1 Agonists: Risks of Grey-Market Semaglutide and Tirzepatide
- FDA-approved GLP-1 agonists (semaglutide: Ozempic/Wegovy; tirzepatide: Mounjaro/Zepbound) are legitimate, extensively studied medications for diabetes and weight loss.
- Compounded versions sold by online pharmacies and medi-spas are NOT the same product , they use unapproved salt forms (semaglutide sodium, semaglutide acetate) that have never been studied in humans.
- The FDA has issued explicit warnings: compounded GLP-1s have been associated with dosing errors, adverse events, and products containing incorrect active ingredients.
- Legitimate GLP-1 agonists are FDA-regulated and manufactured under strict quality standards. Compounded versions are not.
- This is a case where the legitimate pharmaceutical is well-studied, and the “alternative” is the dangerous one , the opposite of the other fad supplement categories.
The Legitimate GLP-1 Revolution
GLP-1 (glucagon-like peptide-1) receptor agonists represent one of the most significant pharmaceutical advances of the past decade. Semaglutide (Ozempic for diabetes, Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) have demonstrated:
- 15-22% body weight reduction in clinical trials (tirzepatide at highest dose)
- Significant improvements in glycemic control
- Cardiovascular risk reduction (semaglutide)
- Favorable safety profiles established in trials involving thousands of participants
These are legitimate, FDA-approved medications backed by large-scale randomized controlled trials. They are manufactured by Novo Nordisk and Eli Lilly under rigorous pharmaceutical quality standards. They are not supplements. They are not “natural alternatives.” They are prescription drugs , well-studied, well-regulated, and effective.
The Grey Market Problem
The legitimate GLP-1 agonists have been in persistent shortage due to overwhelming demand. This shortage, combined with high out-of-pocket costs ($900-1,300/month without insurance), has created a thriving grey market for “compounded” versions.
Compounding pharmacies are permitted by the FDA to prepare customized medications when FDA-approved products are unavailable or unsuitable for a specific patient. During the GLP-1 shortage, many pharmacies began offering compounded semaglutide and tirzepatide , often marketed aggressively through online telehealth platforms and medi-spas at lower prices ($200-500/month).
The problem is that many of these compounded products are not what they claim to be.
The Salt Form Problem
The most significant safety concern involves the active ingredient itself. Novo Nordisk’s semaglutide is formulated as the free base. Many compounded versions use semaglutide sodium or semaglutide acetate , different salt forms of the molecule.
These salt forms have never been studied in humans. No clinical trial has evaluated their safety, efficacy, or pharmacokinetics. They are chemically distinct from the FDA-approved drug. The FDA has explicitly stated that these salt forms “have not been proven to be safe and effective.”
Novo Nordisk has tested these salt forms and found they are not suitable for pharmaceutical use due to stability and purity concerns. The company’s research, submitted to the FDA, demonstrated that semaglutide sodium and acetate degrade more rapidly and form impurities that the approved free base form does not.
Purchasing compounded semaglutide sodium is not equivalent to purchasing “generic semaglutide” , it is purchasing an untested chemical cousin of the approved drug.
FDA Actions and Warnings
The FDA has taken escalating action against the compounding of GLP-1 agonists:
- Multiple warning letters issued to compounding pharmacies and telehealth platforms making false or misleading claims
- Explicit statements that semaglutide sodium and acetate are not the same as FDA-approved semaglutide
- Adverse event reports including dosing errors (patients receiving 5-10x the intended dose from compounding errors), serious gastrointestinal events, and products testing negative for any active ingredient
- Import alerts on bulk semaglutide ingredients from unregistered foreign manufacturers
In 2024-2025, the FDA received reports of compounded semaglutide products that contained nothing more than mannitol (a sugar alcohol filler), products contaminated with bacteria, and products labeled as one dose containing ten times that amount.
How to Identify Legitimate vs. Compounded Products
This is a rare case where the distinction actually matters for safety. Here’s how to tell the difference:
| FDA-Approved | Compounded | |
|---|---|---|
| Product name | Ozempic, Wegovy, Mounjaro, Zepbound | “Semaglutide,” “Tirzepatide,” “GLP-1” |
| Form | Prefilled injection pen with locked dosing | Vial and syringe (dose drawn manually) |
| Active ingredient | Semaglutide free base or tirzepatide | Often “semaglutide sodium” or “semaglutide acetate” |
| Manufacturer | Novo Nordisk or Eli Lilly | Various compounding pharmacies |
| FDA reviewed | Yes . NDA approved | No |
| Manufacturing standards | cGMP pharmaceutical grade | May vary significantly |
| Price | $900-1,300/month (list) | $200-500/month |
If your product comes in a vial with a separate syringe rather than a prefilled injection pen; if the label says “semaglutide sodium” or “semaglutide acetate”; or if it was prescribed after a brief online questionnaire without lab work or medical history review , you are likely using a compounded product with unverified safety and efficacy.
What About Peptide Sellers?
Beyond compounding pharmacies, an even more dangerous tier exists: direct-to-consumer peptide sellers marketing “semaglutide” or “tirzepatide” as “research chemicals” , the same model used for BPC-157 and TB-500. These products are manufactured overseas with zero quality control, no FDA oversight, and no verification of contents or purity.
These sellers are exploiting the GLP-1 shortage to sell products that may contain anything from the correct peptide to completely different substances. A 2025 investigation found that multiple “semaglutide” products sold online contained no detectable GLP-1 agonist whatsoever.
Conclusion
The GLP-1 agonist story is the inverse of the BPC-157 and CJC-1295 stories. With peptides, the unregulated grey-market products are the only option because no approved version exists. With GLP-1s, highly effective FDA-approved medications exist , and the grey market sells inferior, potentially dangerous imitations.
If you are considering GLP-1 therapy for diabetes or weight loss:
- Obtain it through a licensed physician prescribing the FDA-approved product
- If cost is prohibitive, explore manufacturer patient assistance programs (Novo Nordisk and Eli Lilly both offer them) rather than turning to compounding pharmacies
- Never purchase “research” GLP-1 agonists from online peptide sellers
The legitimate medications exist. They work. They are extensively studied. The compounded alternatives are not the same thing, and the risks are not theoretical , they are documented in FDA adverse event reports.
References
[2] FDA. Interim Policy on Compounding Using Bulk Drug Substances. 2023.
[6] CNN/Associated Press. “The trend of unproven peptides.” November 2025.